METOPROLOL SUCCINATE SUSTAINED RELEASE MATRIX TABLETS- FORMULATION DEVELOPMENT AND INVITRO EVALUATION

Objective: Metoprolol succinate is a Beta 1 selective antagonist used as an Anti hypertensive, Anti angina, Anti arrhythmic. The aim of present investigation was to develop matrix tablets of Metoprolol succinate using different polymers. Methods: Metoprolol succinate matrix tablets were prepared by direct compression and wet granulation method using different polymers. All the formulations were evaluated for weight variation, thickness, hardness, friability and dissolution. Results: It has been studied that a matrix tablet containing hydroxyl propyl methyl cellulose polymers for oral controlled delivery of Metoprolol succinate has been formulated with greater significance; hence it was decided to check the in-vitro drug-polymer study in formulating a sustained release tablet for Metoprolol succinate. All the formulations are prepared by using polymers include HPMC K15M, HPMC K100M, Ghatti gum, Sodium CMC, Pectin. All the formulation is subjected to invitro dissolution studies. Conclusion: Among all these formulations F-11 is optimized. This formulation containing 50mg of drug, 150mg of HPMC K15M, 3mg of Mg stearate, 3mg of talc, and 69mg of MCC. As the result of this study it may conclude that the formulation meet the needed theoretical drug release profile and has the sustain action i.e., retarding the drug release so the release is for a long time and thus more bio availability